Results 131 to 140 of about 214,611 (264)
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang +21 more
wiley +1 more source
Chenfei Zhou,1,* Xiaojing Feng,2,* Fei Yuan,3 Jun Ji,4 Min Shi,1 Yingyan Yu,4 Zhenggang Zhu,1,4 Jun Zhang1 1Department of Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 2Department ...
Yuan F +7 more
core
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Shiyang Liu +7 more
wiley +1 more source
Leveraging Microphysiological Systems to Facilitate Neutrophil‐Based Cancer Immunotherapy
Microphysiological systems are emerging as powerful human‐relevant platforms for studying neutrophil biology in cancer. Current applications of spheroids, organoids, and organ‐on‐a‐chip models are reviewed, together with future opportunities in behaviorome profiling, multi‐omics integration, personalized medicine, immune crosstalk, and multi‐organ ...
Shuai Shao +2 more
wiley +1 more source
SOX30 drives triple‐negative breast cancer (TNBC) metastasis through a dual mechanism: direct activation of the TNFR2/NF‐κB signaling cascade and subsequent CCL20‐mediated recruitment of tumor‐associated macrophages (TAMs) into the tumor microenvironment.
Pingping Gao +10 more
wiley +1 more source
Biomimetic Scaffold‐Based 3D Models for Decoding Cancer Biology and Advancing Therapy
A timeline of the research history of 3D biomimetic scaffold materials and platforms. With advances in biomimetic materials and 3D scaffold technologies, their functional scope has expanded from mimicking basic physical and biochemical properties to increasingly replicating complex pathophysiological processes.
Haitao Zhao +10 more
wiley +1 more source
A HER3‐targeted sonogenetic lipid nanoparticle platform is developed for triple‐negative breast cancer therapy. An AI‐designed miniprotein inhibits HER3 signaling, while TRPV4 and NFAT‐responsive IL‐15 plasmids enable ultrasound‐controlled calcium signaling and cytokine expression. The system induces Ca2+ overload, ROS generation, mitochondrial damage,
Junya Song +6 more
wiley +1 more source
High‐density type I collagen promotes glutamine (Gln) accumulation–related ferroptosis of TNBC cells via the spermidine/spermine N1‐acetyltransferase 1 (SAT1)‐ argininosuccinate synthase (ASS1) signaling pathway, thus depriving immune cells of Gln supply and inducing IFN‐γ+ CD8+ T cell exhaustion in the TME.
Jinyan Wang +11 more
wiley +1 more source
Coexisting DCIS and IDC samples are profiled using spatial transcriptomics, single‐cell RNA sequencing, and single‐cell DNA sequencing. Integrative multi‐omics analysis reveals distinct malignant epithelial and microenvironmental features between DCIS and IDC, which are further validated using Xenium and multiplex immunohistochemistry.
Ning Zhang +18 more
wiley +1 more source
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen +10 more
wiley +1 more source

